Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etoposide in prostate cancer.

J M Kamradt1, K J Pienta

  • 1University of Michigan Medical Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA. kpienta@umich.edu

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells.

Proceedings of the National Academy of Sciences of the United States of America·2021
Same author

Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy.

Seminars in cancer biology·2020
Same author

Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.

Medical oncology (Northwood, London, England)·2020
Same author

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Prostate cancer and prostatic diseases·2016
Same author

Detection of apoptosis in renal cell carcinoma.

Methods in molecular medicine·2011
Same author

The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites.

Leukemia·2008

Novel chemotherapy regimens combining oral etoposide show promise for hormone refractory prostate cancer. Early trials suggest these treatments may improve survival, pending further Phase III investigation.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Hormone refractory prostate cancer (HRPC) is an aggressive disease with limited treatment options.
  • Current single-agent chemotherapy offers no survival advantage for HRPC patients.
  • Etoposide, as a standalone treatment, has shown limited efficacy in both intravenous (IV) and oral forms.

Purpose of the Study:

  • To evaluate novel treatment regimens for hormone refractory prostate cancer.
  • To assess the efficacy of combined oral etoposide therapies in HRPC.
  • To explore potential survival benefits of new etoposide-based combinations.

Main Methods:

  • Review of Phase II clinical trials involving novel treatment regimens.
  • Focus on combination therapies incorporating oral etoposide.

Related Experiment Videos

  • Analysis of early survival data from these trials.

    • Main Results:

    • Several combination regimens using oral etoposide demonstrated promising outcomes in Phase II trials.
    • Early data suggest a potential increase in survival for HRPC patients on these novel regimens.
    • These findings highlight the potential of etoposide combination therapy.

    Conclusions:

    • Combination therapy with oral etoposide represents a promising avenue for HRPC treatment.
    • Further Phase III trials are necessary to confirm survival benefits.
    • Novel etoposide-based regimens may offer improved outcomes for advanced prostate cancer.